Clasificación en acciones
#18693
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused... Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Precio por acción
$4.58
Última sincronización: 2025-02-06
Capitalización bursátil
$189.73M
Comercio Axcella Health Inc. (AXLA)
Precio AXLA con Capital del mercado a B
Capitalización de mercado de Axcella Health Inc.(AXLA)
Capitalización bursátil: $189.73M
A fecha de August 2026, Axcella Health Inc. tiene una capitalización de mercado de $189.73M. Esto convierte a Axcella Health Inc. en la 18693rd empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Axcella Health Inc. desde 2019 hasta 2026
AXLA en comparación con los más populares 5 títulos stocks
| Precio por AXLA |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.088T
|
+2,681,511.29%
|
|
|
|
|
$4.629T
|
+2,439,708.64%
|
|
|
|
|
$4.108T
|
+2,165,321.61%
|
|
|
|
|
$3.687T
|
+1,943,019.60%
|
|
|
|
|
$2.800T
|
+1,475,480.92%
|
